ArticlePloS one2015
Carbapenem-nonsusceptible Enterobacteriaceae in Taiwan.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 105 citations in OpenAlex.
- A Systematic Review and Meta-analyses of the Clinical Epidemiology of Carbapenem-Resistant Enterobacteriaceae.Antimicrobial agents and chemotherapy · 2018Pooled it
- Dual resistance to carbapenems and colistin inEmerging microbes & infections · 2026Article
- Chitosan mitigates pan drug resistance in citrobacter freundii exhibiting AmpC and ESBL from Egyptian livestock.Scientific reports · 2025Article
- Antibiotic resistance pattern of multidrug-resistant Enterobacterales from a rectal surveillance study in northern Nigeria.International health · 2025Article
- Infections caused by clonal spread of metallo-beta-lactamase-producingMicrobiology spectrum · 2025Article
- Encoding Genes of Metallo β-Lactamases (Health science reports · 2025Review
- Two virulent bacteriophages targeting carbapenem-resistantFrontiers in microbiology · 2025Article
- Evaluation of the BD Phoenix CPO Detect Panel for Detection and Classification of Carbapenemase ProducingAntibiotics (Basel, Switzerland) · 2023Article
- The Resistance Mechanisms and Clinical Impact of Resistance to the Third Generation Cephalosporins in Species ofAntibiotics (Basel, Switzerland) · 2022Article
- Molecular Epidemiology, Risk Factors and Clinical Outcomes of Carbapenem-NonsusceptiblePathogens (Basel, Switzerland) · 2022Article
- Phenotypic and molecular characterization of IMP-producing Enterobacterales in Spain: Predominance of IMP-8 inFrontiers in microbiology · 2022Article
- Genotypic and Phenotypic Expression of Antibiotic Resistance Patterns of Uropathogenic Enterobacteriaceae.Infection and drug resistance · 2022Article
- Comparative Genomics Revealed Fluoroquinolone Resistance Determinants and OmpF Deletion in Carbapenem-ResistantFrontiers in microbiology · 2022Article
- Epidemiology and high incidence of metallo-β-lactamase and AmpC-β-lactamases in nosocomialIranian journal of basic medical sciences · 2021Article
- Fecal Carriage and Epidemiology of Extended-Spectrum Beta-Lactamase/Carbapenemases Producing Enterobacterales Isolates in Bulgarian Hospitals.Antibiotics (Basel, Switzerland) · 2021Article
- Molecular Epidemiology and Characterization of Carbapenem-ResistantMicroorganisms · 2021Article
- Increasing New Delhi metallo-β-lactamase-positive Escherichia coli among carbapenem non-susceptible Enterobacteriaceae in Taiwan during 2016 to 2018.Scientific reports · 2021Article
- Epidemiology of resistance and phenotypic characterization of carbapenem resistance mechanisms inAfrican health sciences · 2019Article
- Risk factors for carbapenem-resistant Enterobacteriaceae infections: a French case-control-control study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2019Article
- Emergence of NDM-1- and CTX-M-3-ProducingFrontiers in microbiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A total of 1135 carbapenem-resistant (nonsusceptible) Enterobacteriaceae (CRE) isolates were recovered between November 2010 and July 2012 (517 from 2010-2011 and 618 from 2012) from 4 hospitals in Taiwan. Carbapenemase-producing Enterobacteriaceae (CPE) comprised 5.0% (57 isolates), including 17 KPC-2 (16 Klebsiella pneumoniae and 1 Escherichia coli), 1 NDM-1 (K. oxytoca), 37 IMP-8 (26 Enterobacter cloacae, 4 Citrobacter freundii, 4 Raoultella planticola, 1 K. pneumoniae, 1 E. coli and 1 K. oxytoca), and 2 VIM-1 (1 E. cloacae, 1 E. coli). The KPC-2-positive K. pneumoniae were highly clonal even in isolates from different hospitals, and all were ST11. IMP-8 positive E. cloacae from the same hospitals showed higher similarity in PFGE pattern than those from different hospitals. A total of 518 CRE isolates (45.6%) were positive for blaESBL, while 704 (62.0%) isolates were blaAmpC-positive, 382 (33.6% overall) of which carried both blaESBL and blaAmpC. CTX-M (414, 80.0%) was the most common blaESBL, while DHA (497, 70.6%) and CMY (157, 22.3%) were the most common blaAmpC. Co-carriage of blaESBL and blaAmpC was detected in 31 (54.4%) and 15 (26.3%) of the 57 CPE, respectively. KPC-2 was the most common carbapenemase detected in K. pneumoniae (2.8%), while IMP-8 was the most common in E. cloacae (9.7%). All KPC-2-positive CRE were resistant to all three tested carbapenems. However, fourteen of the 37 IMP-8-positive CRE were susceptible to both imipenem and meropenem in vitro. Intra- and inter-hospital spread of KPC-2-producing K. pneumoniae and IMP-8-producing E. cloacae likely occurred. Although the prevalence of CPE is still low, careful monitoring is urgently needed. Non-susceptibility to ertapenem might need to be considered as one criterion of definition for CRE in areas where IMP type carbapenemase is prevalent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.